At the heart of Eli Lilly's recent success and future prospects lies its formidable GLP-1 portfolio, headlined by Mounjaro (tirzepatide) and Zepbound. These drugs have shown remarkable efficacy in ...

Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of ...

Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

At the heart of Eli Lilly's growth story is its robust portfolio of GLP-1 drugs. Mounjaro and Zepbound have shown impressive prescription growth trends, with Mounjaro experiencing a 21.6% ...

While Ozempic mimics one hunger-relieving hormone, and Mounjaro mimics two, Eli Lilly is working on what's called a "triple agonist," with three different hormone-like substances inside.

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...

(WHNT) — The Alabama Department of Public Health issued a statement Wednesday about its current investigation into certain “adverse events” following an injection. In the news release ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.

The main growth driver for Eli Lilly is the successful incretin portfolio, specifically the duo Mounjaro and Zepbound. Mounjaro's Q3 2024 performance was nothing short of exceptional, with global ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...